Real Time Molecular Analysis of Breast Cancer Receiving Neo-adjuvant Chemotherapy
ConditionBreast Cancer Female
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorInstitut Paoli-Calmettes
About this trial
The present project aims at identifying robust candidates for drug resistance in BC patients eligible for NAC. Its originality lies upon the combination of three different and complementary prospective approaches: from the molecular analyses of biopsies sampled before and after NAC, from in vitro BC Patient-Derived Organoids (PDO) mimicking patient's response to NAC, and from Circulating Tumor Cells (CTCs) isolated before/during/after NAC.
Eligibility criteria
Qualifiers
Woman over 18
Signed consent to participate
Invasive mammary adenocarcinoma proven histologically and / or cytologically
Indication of CNA retention by the referring clinical team.
Disqualifiers
Planned therapeutic sequence: CNA, followed by neoadjuvant radiotherapy (HIST-RIC clinical trial for example) before surgery
Metastatic disease at diagnosis
Patient relapsed from breast cancer precede
Other malignant disease in the previous 3 years, with the exception of cervical carcinoma in situ or skin basal cell carcinoma and any other cancerous pathology considered to have been properly treated and at low risk of relapse.
Trial design
Treatments tested in this trial
- molecular analysis of blood and tumor
Treatment groups
150 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov